Methotrexate is a medication commonly used in the treatment of various conditions, including cancer, rheumatoid arthritis, and psoriasis. However, it is important to consider the potential side effects and risks associated with its use, particularly in children.
According to the sources provided, there is limited information specifically addressing the potential developmental delays caused by methotrexate in children. The Drug Patent Watch website [1] does not mention developmental delays as a known side effect of methotrexate. However, it is important to note that this source primarily focuses on patent information rather than detailed medical data.
The National Center for Biotechnology Information (NCBI) book [2] on methotrexate does not specifically mention developmental delays as a side effect either. However, it does state that methotrexate can cause various adverse effects, including gastrointestinal disturbances, hepatotoxicity, and bone marrow suppression. These side effects are more commonly observed in higher doses and prolonged use of the medication.
A study published in PubMed [3] investigated the long-term effects of methotrexate treatment in children with juvenile idiopathic arthritis (JIA). The study did not find a significant association between methotrexate use and cognitive or developmental delays in these children. However, the study did acknowledge that further research is needed to fully understand the potential effects of methotrexate on child development.
While the sources provided do not indicate a direct link between methotrexate and developmental delays in children, it is important to consult with a healthcare professional for a comprehensive evaluation of the potential risks and benefits of using methotrexate in pediatric patients. They can provide personalized advice based on the child's specific condition and medical history.
In conclusion, based on the sources provided, there is limited evidence to suggest that methotrexate causes developmental delays in children. However, it is essential to consult with a healthcare professional for a thorough evaluation of the potential risks and benefits of using methotrexate in pediatric patients.
Sources:
[1] Drug Patent Watch: Methotrexate. Retrieved from https://www.drugpatentwatch.com/p/tradename/METHOTREXATE
[2] National Center for Biotechnology Information (NCBI) Bookshelf: Methotrexate. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK582834/
[3] PubMed: Longterm outcome of methotrexate therapy in juvenile idiopathic arthritis. Retrieved from https://pubmed.ncbi.nlm.nih.gov/10413333/